A phase I–II study (NCT03046992), enrolling patients with advanced NSCLC harboring activating mutations of EGFR who had progressed after EGFR TKI therapy, had further proved its tolerable safety profile and promising clinical activity (28). This evidence concerns the gene EGFR and non-small cell lung carcinoma.